Novel Androgen Deprivation Treatment for Advanced Prostate Cancer: Optimizing Benefits, Mitigating Risk

Target Audience
This activity is designed to meet the educational needs of medical oncologists, nurse practitioners, and other healthcare professionals who care for patients with prostate cancer.

Program Overview
Join Drs. Robert Dreicer and Michael Cookson as they review the principles of androgen deprivation therapy and discuss the latest clinical data for recently approved ADT agents and studies of ADT-based combination regimens in the treatment of men with metastatic hormone sensitive prostate cancer (mHSPC). The evolving guideline-directed evidence-based approaches for therapeutic intensification in the treatment of mHSPC are also discussed. Listen to the faculty discuss case studies to gain practical insights into choosing optimal therapies that incorporate ADT for individual patients and balance patient preferences with therapeutic goals.

Learning Objectives
Upon completion of this activity, participants should be better able to:

Explain the differences between luteinizing hormone-releasing hormone agonists and gonadotropin-releasing hormone antagonists in terms of mechanism of action and outcomes
Select optimal therapy to avoid/reduce cardiovascular risk in patients with advanced prostate cancer
Compare and contrast the latest evidence regarding options for patients with advanced prostate cancer
Develop treatment strategies incorporating patient-specific factors, including risk factors, concerns, preferences, and adherence information regarding oral vs injectable oncologic therapy